Core Insights - Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner for focal onset seizures, demonstrating significant efficacy and safety [1][2][3] Study Results - The study met its primary endpoint with a median percent change (MPC) in monthly focal onset seizure frequency of -53.2% for the 25 mg dose and -34.5% for the 15 mg dose compared to -10.4% for placebo (p=0.000000000006 for 25 mg) [2][5] - The placebo-adjusted MPC for the 25 mg group was -42.7%, outperforming the Phase 2b X-TOLE study which had a -34.6% placebo-adjusted MPC [2][5] - The key secondary endpoint, Responder Rate 50 (RR50), showed 54.8% in the 25 mg group and 37.6% in the 15 mg group achieving at least a 50% reduction in monthly seizure frequency, compared to 20.8% in the placebo group (p=0.00000008 for 25 mg) [7][8] Safety Profile - Azetukalner demonstrated a safety and tolerability profile consistent with prior studies, with common treatment-emergent adverse events including dizziness (20.5%), headache (8.8%), somnolence (8.8%), and fatigue (7.6%) [6][8] - Serious treatment-emergent adverse events were low across treatment groups, with 5.6% in the 25 mg group, 3.2% in the 15 mg group, and 2.4% in the placebo group [8] Future Plans - Xenon plans to submit a New Drug Application (NDA) to the U.S. FDA for azetukalner in the third quarter of 2026, aiming for it to be the only KV7 potassium channel opener available for epilepsy treatment [2][5] - The X-TOLE2 data will be presented at the AAN Annual Meeting in April 2026 [10] Company Overview - Xenon Pharmaceuticals is focused on drug discovery and development for neurological conditions, with azetukalner being the most advanced KV7 potassium channel opener in late-stage clinical trials for epilepsy and other indications [1][16]